Jazz Pharmaceuticals JAZZ Software and Technology Licenses, Net
Software and Technology Licenses, Net at other companies
Other financials
Where this comes from
Reported directly by Jazz Pharmaceuticals in its filing.
Tagged under the XBRL concept us-gaap:OtherAssetsNoncurrent.
The official record: Jazz Pharmaceuticals’s 10-Q, filed May 5, 2026, on SEC EDGAR. View the filing →
Ask your AI about Jazz Pharmaceuticals's software and technology licenses, net.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is Jazz Pharmaceuticals's software and technology licenses, net?
- Jazz Pharmaceuticals (JAZZ) reported software and technology licenses, net of $94.7M in Q1 2026.
- How has Jazz Pharmaceuticals's software and technology licenses, net changed year-over-year?
- Jazz Pharmaceuticals's software and technology licenses, net decreased by 18.7% year-over-year, from $116.52M to $94.7M.
- What is the long-term trend for Jazz Pharmaceuticals's software and technology licenses, net?
- Over 5 years (2020 to 2025), Jazz Pharmaceuticals's software and technology licenses, net has grown at a 30.9% compound annual growth rate (CAGR), from $25.72M to $99M.